Stay updated on Remibrutinib Long-term Extension in Urticaria Clinical Trial
Sign up to get notified when there's something new on the Remibrutinib Long-term Extension in Urticaria Clinical Trial page.

Latest updates to the Remibrutinib Long-term Extension in Urticaria Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page shows a new Revision label, updating from v3.5.3 to v3.5.4, indicating a small build-level update.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedTaoyuan District, Taiwan, 33305 was removed. Taoyuan, Taiwan, 33305 was added in the Locations list, updating the Taiwan site address to reflect current administrative naming.SummaryDifference0.0%

- Check42 days agoChange DetectedUpdated the ClinicalTrials.gov page’s displayed revision/version label from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check49 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This appears to be a backend version update and does not modify study content or user-facing features.SummaryDifference0.0%

- Check78 days agoChange DetectedRevision: v3.5.0 has been added and v3.4.3 has been removed.SummaryDifference0.0%

- Check85 days agoChange DetectedAdded new study locations across multiple countries (examples include Uskudar, Melikgazi, Karsiyaka, Karabaglar, Efeler, Buca, Atakum, Adapazari, Hajdu Bihar Megye, Hesse, Bavaria, Cundinamarca, and more) and removed numerous sites; total locations updated from 207 to 208.SummaryDifference2%

Stay in the know with updates to Remibrutinib Long-term Extension in Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Remibrutinib Long-term Extension in Urticaria Clinical Trial page.